Aspen Pharmacare Logo
ZAE000066692
A0ET80
APN.JO

Aspen Pharmacare

Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Aspen Pharmacare raises forecast after strong profit and cash‑flow increase

    Aspen Pharmacare reports for FY 2026 a normalised headline earnings per share (NHEPS) of 802 cents (+28%), normalised EBITDA of 7.7 billion ZAR (+14%) and free cash flow of 3.8 billion ZAR. Despite largely stagnant revenue, profitability improved through margin increases, lower costs and restructuring effects; the stock rose to near a 52‑week high. Management forecasts for FY 2027 an EBITDA of at least 9 billion ZAR and NHEPS growth of over 50%, supported by strong GLP‑1 growth (including Mounjaro) and a recovery in sterile production. » More on de.investing.com


  • Aspen Pharmacare receives approval for Ozempic generic in Canada

    Health Canada has approved Aspen‑Semaglutide, a generic semaglutide from Aspen Pharmacare for the treatment of type 2 diabetes. The drug is a generic version of Novo Nordisk’s Ozempic, made possible by the patent expiry on semaglutide. Market entry in Canada depends on the availability of the active ingredient from Dr. Reddy’s Laboratories. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics
In 2026, Aspen Pharmacare has already paid €0.13 in dividends. The last payout was in October.

Financials

In the last quarter, Aspen Pharmacare had revenue of €951.42M and net profit of €62.83M
(EUR) June 2026
YoY
Revenue 951.42M -
Gross profit 353.09M -
Net profit 62.83M -
EBITDA 173.95M -

Fundamentals

Metric Value
Market capitalization
€4.08B
Number of shares
4.33M
52-week high/low
€957.52 - €478.71
Dividend yield
1.32%
Dividends TTM
€0.13
Beta
0.30
P/E ratio
29.95
PEG ratio
-0.60
P/B ratio
0.98
P/S ratio
2.22

Company profile

Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general anesthetics, muscle relaxants, and topical agents under the Anaesthetics brand; and a range of injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors, and heparin derivatives under the Thrombosis brand. It also offers branded consumer, prescription, and over-the-counter products under the regional brands, such as Circadin, Foxair, Maltofer, Mybulen, and Zyloric for various types of anesthetic comprises sleeping aid, respiratory, iron supplement, analgesic, and uric acid production inhibitor. In addition, the company manufactures and sells active pharmaceutical ingredients and finished dose form products to third-party customers. The company was founded in 1850 and is headquartered in Durban, South Africa.

Name
Aspen Pharmacare
CEO
Stephen Bradley Saad
Headquarters Durban, nl
South Africa
Website
IPO
01/04/2000
Employees 7,454

Ticker symbols

Exchange Symbol
Jnb
APN.JO
Pnk
APNHF
Frankfurt
LDZA.F
DĂĽsseldorf
LDZA.DU
MĂĽnchen
LDZA.MU
🍪

Parqet  uses cookies. Learn more